LUPIN Financial Statement Analysis
|
||
|
The Revenues of LUPIN have increased by 13.48% YoY .
The Earnings Per Share (EPS) of LUPIN has increased by 62.29 % YoY. |
||
LUPIN Last 5 Annual Financial Results
[BOM: 500257|NSE : LUPIN]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹22,708 Cr | ₹20,011 Cr | ₹16,642 Cr | ₹16,405 Cr | ₹15,163 Cr |
| Expenses | ₹17,430 Cr | ₹16,222 Cr | ₹14,921 Cr | ₹16,190 Cr | ₹12,596 Cr |
| Operating Profit (Excl OI) | ₹5,278 Cr | ₹3,789 Cr | ₹1,721 Cr | ₹215 Cr | ₹2,567 Cr |
| Other Income | ₹202 Cr | ₹142 Cr | ₹151 Cr | ₹214 Cr | ₹136 Cr |
| Interest | ₹295 Cr | ₹312 Cr | ₹274 Cr | ₹143 Cr | ₹141 Cr |
| Depreciation | ₹1,169 Cr | ₹1,197 Cr | ₹881 Cr | ₹1,659 Cr | ₹887 Cr |
| Profit Before Tax | ₹4,015 Cr | ₹2,422 Cr | ₹716 Cr | ₹-1,372 Cr | ₹1,676 Cr |
| Profit After Tax | ₹3,306 Cr | ₹1,936 Cr | ₹448 Cr | ₹-1,509 Cr | ₹1,228 Cr |
| Consolidated Net Profit | ₹3,282 Cr | ₹1,914 Cr | ₹430 Cr | ₹-1,528 Cr | ₹1,217 Cr |
| Earnings Per Share (Rs) | ₹116.64 | ₹71.87 | ₹42.01 | ₹9.45 | ₹-33.62 |
| PAT Margin (%) | 12.42 | 8.89 | 6.10 | 1.57 | -5.09 |
| ROE(%) | 27.11 | 21.13 | 14.61 | 3.68 | -11.79 |
| ROCE(%) | 28.86 | 21.97 | 16.24 | 6.06 | -7.11 |
| Total Debt/Equity(x) | 0.26 | 0.30 | 0.19 | 0.34 | 0.32 |
Key Financials |
||
| Market Cap | : | ₹ 107,899.2 Cr |
| Revenue (TTM) | : | ₹ 29,966.6 Cr |
| Net Profit(TTM) | : | ₹ 5,551.0 Cr |
| EPS (TTM) | : | ₹ 121.4 |
| P/E (TTM) | : | 19.4 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| LUPIN | -0.7% | -5.7% | 24% |
| SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 0.5% | 14% |
| DIVIS LABORATORIES | -0.9% | 21.1% | 25.6% |
| TORRENT PHARMACEUTICALS | -1.3% | 1.1% | 32.7% |
| CIPLA | 0.2% | 2.1% | -5.1% |
| DR REDDYS LABORATORIES | 0.2% | -7.7% | -7.5% |
| MANKIND PHARMA | -1.4% | -3.7% | -5.3% |
| ZYDUS LIFESCIENCES | -0.1% | -3.9% | 14.1% |
| AUROBINDO PHARMA | 4.4% | 4.7% | 39.3% |
LUPIN Revenues
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 13.48 % |
| 5 Yr CAGR | 10.62 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹22,708 Cr | 13.48 | |
| Mar2025 | ₹20,011 Cr | 20.25 | |
| Mar2024 | ₹16,642 Cr | 1.44 | |
| Mar2023 | ₹16,405 Cr | 8.19 | |
| Mar2022 | ₹15,163 Cr | - | |
LUPIN Operating Profit
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 39.28 % |
| 5 Yr CAGR | 19.74 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹5,278 Cr | 39.28 | |
| Mar2025 | ₹3,789 Cr | 120.22 | |
| Mar2024 | ₹1,721 Cr | 699.37 | |
| Mar2023 | ₹215 Cr | -91.61 | |
| Mar2022 | ₹2,567 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 22.70 % |
| 5 Yr CAGR | 8.24 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 23.24% | 22.70 | |
| Mar2025 | 18.94% | 83.17 | |
| Mar2024 | 10.34% | 689.31 | |
| Mar2023 | 1.31% | -92.26 | |
| Mar2022 | 16.93% | - | |
LUPIN Profit After Tax
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 71.41 % |
| 5 Yr CAGR | 28.16 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹3,282 Cr | 71.41 | |
| Mar2025 | ₹1,914 Cr | 345.15 | |
| Mar2024 | ₹430 Cr | Positive | |
| Mar2023 | ₹-1,528 Cr | Negative | |
| Mar2022 | ₹1,217 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 39.71 % |
| 5 Yr CAGR | Positive |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 12.42 % | 39.71 | |
| Mar2025 | 8.89 % | 45.74 | |
| Mar2024 | 6.1 % | 288.54 | |
| Mar2023 | 1.57 % | Positive | |
| Mar2022 | -5.09 % | - | |
LUPIN Earnings Per Share (EPS)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 62.29 % |
| 5 Yr CAGR | Positive |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹117 | 62.29 | |
| Mar2025 | ₹72 | 71.08 | |
| Mar2024 | ₹42 | 344.55 | |
| Mar2023 | ₹9.45 | Positive | |
| Mar2022 | ₹-34 | - | |
LUPIN Return on Capital Employed (ROCE)
[BOM: 500257|NSE : LUPIN]
| Y-o-Y | 31.36 % |
| 5 Yr CAGR | Positive |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 28.86% | 31.36 | |
| Mar2025 | 21.97% | 35.28 | |
| Mar2024 | 16.24% | 167.99 | |
| Mar2023 | 6.06% | Positive | |
| Mar2022 | -7.11% | - | |
LUPIN Share Price vs Sensex
| Current Share Price | : | ₹2,360.0 |
| Current MarketCap | : | ₹ 107,899.2 Cr |
| Updated EOD on | : | Aug 07,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| LUPIN | -0.7% |
-5.7% |
24% |
| SENSEX | 0.5% |
2.6% |
-3.7% |
LUPIN related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 400 MIDSMALLCAP INDEX | 1.7% | 4.2% | 6.6% |
| BSE 150 MIDCAP INDEX | 1.3% | 4.3% | 8% |
| BSE 1000 | 1.3% | 3.7% | 3% |
| BSE 500 | 1.1% | 3.6% | 2.6% |
| BSE SENSEX NEXT 50 | 1% | 4.5% | 6.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY500 MULTICAP INDIA MANUFACTURING 50:30:20 | 2.4% | 6.3% | 12.6% |
| NIFTY INDIA MANUFACTURING | 2% | 5.9% | 16.2% |
| NIFTY500 SHARIAH | 1.9% | 5.5% | 1.2% |
| NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100 INDEX | 1.8% | 4.5% | 5.7% |
| NIFTY MIDSMALL HEALTHCARE | 1.7% | 5.6% | 15.1% |
You may also like the below Video Courses
FAQ about LUPIN Financials
How the annual revenues of LUPIN have changed ?
The Revenues of LUPIN have increased by 13.48% YoY .
How the Earnings per Share (EPS) of LUPIN have changed?
The Earnings Per Share (EPS) of LUPIN has increased by 62.29 % YoY .
Check out Intrinsic Value of Peers of LUPIN
Compare Stock Analytics of Peers of LUPIN
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
